Research Reports | Market Assessment
May 2016

Multiple Sclerosis | Current Treatment | EU5 | 2016

The EU5 market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is dynamic and evolving. More than ten key branded DMTs are available, with several launching in the past five years, each delivering a unique balance of benefit, risk, and convenience. New agents, in particular oral DMTs, have meaningfully altered physician preferences and introduced new complexity into an already complicated treatment paradigm. Understanding the many decision points facing EU5 neurologists in the shifting treatment of MS provides, and in five unique countries, important context for developers of marketed and pipeline DMTs.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports